使用伏替西汀进行为期 8 周的 "TReatment "治疗对阿联酋合并广泛性焦虑症的重度抑郁症患者抑郁症状的疗效(TRUE)。

IF 3.6 3区 医学 Q1 PSYCHIATRY Annals of General Psychiatry Pub Date : 2024-11-01 DOI:10.1186/s12991-024-00526-w
Bassem Badr, Hana Al Gailani, Samia Alkhoori, Hania Butt, Michel Daher, Bassam Dheyaa, Nasser El Hindy, Mohamed Wafeek Eid, Nisrin Elsaadouni, Valentina Faia, Alaa Haweel, Tarek Khammas, Hussein Omar, George Tadros, Charles Yacoub, Tamer Talaat, Ahmed El-Shafei
{"title":"使用伏替西汀进行为期 8 周的 \"TReatment \"治疗对阿联酋合并广泛性焦虑症的重度抑郁症患者抑郁症状的疗效(TRUE)。","authors":"Bassem Badr, Hana Al Gailani, Samia Alkhoori, Hania Butt, Michel Daher, Bassam Dheyaa, Nasser El Hindy, Mohamed Wafeek Eid, Nisrin Elsaadouni, Valentina Faia, Alaa Haweel, Tarek Khammas, Hussein Omar, George Tadros, Charles Yacoub, Tamer Talaat, Ahmed El-Shafei","doi":"10.1186/s12991-024-00526-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Major Depressive Disorder (MDD) is a leading cause of disability and results in excessive utilization of healthcare resources worldwide. The Middle East and North Africa (MENA) region shows a high prevalence of depressive disorders. Generalized Anxiety Disorder (GAD) and MDD have the highest rate of comorbidity of all mood and anxiety disorders, ranging from 40 to 98% in drug studies. Comorbid GAD results in more significant impairment in MDD and increases the severity of symptoms. Although several clinical trials supported the safety and effectiveness of vortioxetine, no data regarding these aspects has been revealed in the MENA region. This study aimed to assess the safety and efficacy of vortioxetine in patients with comorbid GAD in the United Arab Emirates (UAE).</p><p><strong>Method: </strong>In a multicenter observational study, 118 patients with confirmed anxiety and depressive disorders were evaluated over four visits (baseline visit, two weeks, four weeks, and eight weeks) using MADRS and HAM-A scales to assess depression and anxiety severity, respectively by calculating mean change and the percent using Kendall's W test.</p><p><strong>Results: </strong>A significant mean difference in MADRS score was observed, with a gradual decrease of mean MADRS total scores over the assessment weeks (p < 0.001) as well as in HAM-A scores, from severe to moderate-severe anxiety through the four visits (p < 0.001). Furthermore, only one case was reported as a serious side effect. Nausea and insomnia were the most predominant side effects reported among the studied population.</p><p><strong>Conclusion: </strong>Vortioxetine was found effective and safe among patients with MDD and comorbid GAD.</p>","PeriodicalId":7942,"journal":{"name":"Annals of General Psychiatry","volume":"23 1","pages":"41"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531123/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of 8-week TReatment with vortioxetine on depressive symptoms in major depressive disorder patients with comorbid generalized anxiety disorder in UAE (TRUE).\",\"authors\":\"Bassem Badr, Hana Al Gailani, Samia Alkhoori, Hania Butt, Michel Daher, Bassam Dheyaa, Nasser El Hindy, Mohamed Wafeek Eid, Nisrin Elsaadouni, Valentina Faia, Alaa Haweel, Tarek Khammas, Hussein Omar, George Tadros, Charles Yacoub, Tamer Talaat, Ahmed El-Shafei\",\"doi\":\"10.1186/s12991-024-00526-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Major Depressive Disorder (MDD) is a leading cause of disability and results in excessive utilization of healthcare resources worldwide. The Middle East and North Africa (MENA) region shows a high prevalence of depressive disorders. Generalized Anxiety Disorder (GAD) and MDD have the highest rate of comorbidity of all mood and anxiety disorders, ranging from 40 to 98% in drug studies. Comorbid GAD results in more significant impairment in MDD and increases the severity of symptoms. Although several clinical trials supported the safety and effectiveness of vortioxetine, no data regarding these aspects has been revealed in the MENA region. This study aimed to assess the safety and efficacy of vortioxetine in patients with comorbid GAD in the United Arab Emirates (UAE).</p><p><strong>Method: </strong>In a multicenter observational study, 118 patients with confirmed anxiety and depressive disorders were evaluated over four visits (baseline visit, two weeks, four weeks, and eight weeks) using MADRS and HAM-A scales to assess depression and anxiety severity, respectively by calculating mean change and the percent using Kendall's W test.</p><p><strong>Results: </strong>A significant mean difference in MADRS score was observed, with a gradual decrease of mean MADRS total scores over the assessment weeks (p < 0.001) as well as in HAM-A scores, from severe to moderate-severe anxiety through the four visits (p < 0.001). Furthermore, only one case was reported as a serious side effect. Nausea and insomnia were the most predominant side effects reported among the studied population.</p><p><strong>Conclusion: </strong>Vortioxetine was found effective and safe among patients with MDD and comorbid GAD.</p>\",\"PeriodicalId\":7942,\"journal\":{\"name\":\"Annals of General Psychiatry\",\"volume\":\"23 1\",\"pages\":\"41\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531123/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of General Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12991-024-00526-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of General Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12991-024-00526-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

背景:重度抑郁症(MDD)是导致残疾的主要原因之一,并导致全球医疗资源的过度使用。中东和北非地区(MENA)的抑郁症发病率很高。在所有情绪和焦虑症中,广泛性焦虑症(GAD)和 MDD 的合并率最高,在药物研究中,合并率从 40% 到 98% 不等。合并 GAD 会对 MDD 造成更严重的损害,并增加症状的严重性。尽管多项临床试验证实了伏替西汀的安全性和有效性,但在中东和北非地区尚未发现有关这些方面的数据。本研究旨在评估伏替西汀在阿拉伯联合酋长国(UAE)合并 GAD 患者中的安全性和有效性:在一项多中心观察性研究中,118 名确诊为焦虑症和抑郁症的患者接受了四次访视(基线访视、两周、四周和八周),分别使用 MADRS 和 HAM-A 量表评估抑郁和焦虑的严重程度,使用 Kendall's W 检验计算平均变化和百分比:结果:观察到 MADRS 评分的平均值有明显差异,MADRS 总分的平均值在评估周内逐渐下降(p 结论:沃替西汀对抑郁症和焦虑症患者有效:发现伏替西汀对 MDD 和合并 GAD 患者有效且安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effectiveness of 8-week TReatment with vortioxetine on depressive symptoms in major depressive disorder patients with comorbid generalized anxiety disorder in UAE (TRUE).

Background: Major Depressive Disorder (MDD) is a leading cause of disability and results in excessive utilization of healthcare resources worldwide. The Middle East and North Africa (MENA) region shows a high prevalence of depressive disorders. Generalized Anxiety Disorder (GAD) and MDD have the highest rate of comorbidity of all mood and anxiety disorders, ranging from 40 to 98% in drug studies. Comorbid GAD results in more significant impairment in MDD and increases the severity of symptoms. Although several clinical trials supported the safety and effectiveness of vortioxetine, no data regarding these aspects has been revealed in the MENA region. This study aimed to assess the safety and efficacy of vortioxetine in patients with comorbid GAD in the United Arab Emirates (UAE).

Method: In a multicenter observational study, 118 patients with confirmed anxiety and depressive disorders were evaluated over four visits (baseline visit, two weeks, four weeks, and eight weeks) using MADRS and HAM-A scales to assess depression and anxiety severity, respectively by calculating mean change and the percent using Kendall's W test.

Results: A significant mean difference in MADRS score was observed, with a gradual decrease of mean MADRS total scores over the assessment weeks (p < 0.001) as well as in HAM-A scores, from severe to moderate-severe anxiety through the four visits (p < 0.001). Furthermore, only one case was reported as a serious side effect. Nausea and insomnia were the most predominant side effects reported among the studied population.

Conclusion: Vortioxetine was found effective and safe among patients with MDD and comorbid GAD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.60
自引率
2.70%
发文量
43
审稿时长
>12 weeks
期刊介绍: Annals of General Psychiatry considers manuscripts on all aspects of psychiatry, including neuroscience and psychological medicine. Both basic and clinical neuroscience contributions are encouraged. Annals of General Psychiatry emphasizes a biopsychosocial approach to illness and health and strongly supports and follows the principles of evidence-based medicine. As an open access journal, Annals of General Psychiatry facilitates the worldwide distribution of high quality psychiatry and mental health research. The journal considers submissions on a wide range of topics including, but not limited to, psychopharmacology, forensic psychiatry, psychotic disorders, psychiatric genetics, and mood and anxiety disorders.
期刊最新文献
Psychotropic drug-induced adverse drug reactions in 462,661 psychiatric inpatients in relation to age: results from a German drug surveillance program from 1993-2016. Clinical patterns of metabolic syndrome in young, clinically stable, olanzapine-exposed patients with schizophrenia. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review. A pooled analysis of the efficacy of sertraline in women, with a focus on those of childbearing age. Treatment satisfaction and effectiveness of Lurasidone on quality of life and functioning in adult patients with schizophrenia in the real-world Italian clinical practice: a prospective 3-month observational study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1